Genewity is excited to announce the appointment of Willem-Jan Krebber as Chief Operating Officer (COO), effective September 2024. His appointment is a key step in the company’s transition to advance clinical and commercial production. With over 20 years of experience in biopharmaceutical operations, Willem-Jan brings strong expertise in product development, Good Manufacturing Practices (GMP) manufacturing, and GMP compliance, which will be critical as Genewity advances its gene-modified cell therapy, i-Thymus, toward clinical stage.

Before joining Genewity, Willem-Jan served as COO at ISA Pharmaceuticals, where he led the shift of immunotherapies from early-stage research to late stage clinical GMP-manufacturing. His prior roles at OctoPlus and Crucell (now part of Janssen Vaccines) have strengthened his skills in operations, process optimisation, vendor selection, and managing large-scale productions. This experience will be invaluable as Genewity builds its own production network and scales up its pipeline.

Willem-Jan’sdeep knowledge of Chemistry, Manufacturing, and Controls (CMC) will ensure thatthe company meets regulatory standards while maintaining cost-effective,high-quality production. His leadership will also guide the selection andmanagement of trusted manufacturing partners to ensure the reliable delivery oftherapies to market.

“Willem-Jan’s experience in scaling biotech operations will be key as we move forward,” says Arno Bisschop, CEO of Genewity. “His expertise in both the technical and strategic aspects of manufacturing will be vital to our mission of making a difference for patients.”

With this appointment, Genewity is strengthening its operational foundations and positioning itself for global success, led by Willem-Jan’s strategic vision and extensive experience in GMP and CMC.

‍